Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01257698 · ClinicalTrials.gov registry record · NA
Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy
A NA study, sponsored by Mid Atlantic Retina.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT01257698: Completed NA study, sponsored by Mid Atlantic Retina.
NCT01257698 is a NA study that has completed, run by Mid Atlantic Retina. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01257698, a NA study, has completed, sponsored by Mid Atlantic Retina.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to see if glaucoma eye drops (dorzolamide-timolol) have any effect on the duration of an intraocular gas bubble following pars plana vitrectomy.
Primary Outcome
Patients will self-monitor gas bubble duration and will receive weekly phone calls by the study coordinator until gas disappearance is confirmed.
Interventions
- DRUG Dorzolamide 2%-timolol 0.5% topical eyedrops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-06 |
| Phase | NA |
What the finished NCT01257698 record still lists
NCT01257698 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Dorzolamide 2%-timolol 0.5% topical eyedrops is the first listed.
NCT01257698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01257698 about?
NCT01257698 is a clinical study titled "Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy". The purpose of this study is to see if glaucoma eye drops (dorzolamide-timolol) have any effect on the duration of an intraocular gas bubble following pars plana vitrectomy.
What is the current status of trial NCT01257698?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2010-02. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01257698?
The interventions under investigation include: Dorzolamide 2%-timolol 0.5% topical eyedrops (DRUG).
Who is sponsoring clinical trial NCT01257698?
This trial is sponsored by Mid Atlantic Retina, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01257698's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia